At a glance
ClinicalIndex Comparison RecordN/ACompleted· 65 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PMOS: Kaletra Double Protease Inhibitors
In Brief
An observational study for Human Immunodeficiency Virus. Completed, enrolled 65 participants across 17 sites.
Detailed Summary
Therapy with lopinavir/ritonavir (Kaletra) and one other protease inhibitor in Human Immunodeficiency Virus participants
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2004
First PostedFeb 2010
Primary CompletionSep 2011
TodayJul 2026
First PostedFeb 25, 2010
Enrollment StartJan 1, 2004
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 16.4 years ago